How predictive is PK/PD for antibacterial agents?
The pharmacodynamic (PD) parameters most often used in studies of antibiotic effect include the following relationships between the antibiotic concentration curve in serum as a surrogate marker for the antibiotic concentration at the infection site, the peak/minimal inhibitory concentration (MIC) ratio, the area under the curve (AUC)/MIC ratio and the duration of time the concentration exceeds the MIC (T(>MIC)). The MIC plays an important role also as a PD marker, and its precision in this respect is discussed. The predictive role of T(>MIC) is important for drugs showing minimal concentration dependent effect such as the beta-lactam antibiotics, the macrolides and others. The time can be calculated as the chronological time measured or as the (cumulative) per cent of the dosing interval covered by the dose. Several clinical studies have confirmed this relationship. It can be deduced from experimental as well as clinical studies that there is a minimal effective time (MET), which needs to be covered by the antibiotic concentration at the site of infection in order to achieve cure. Dosing according to this MET will result in the least antibiotic needed for the shortest duration. In several cases a single dose will suffice to cover the MET. If this is not possible the antibiotic should be dosed in a way, that each dose will surpass the MIC for at least 40-50% of the dosing interval. For antibiotics with a clear concentration-dependent bacterial killing effect the most important pharmacokinetic/pharmacodynamic (PK/PD) index is the peak/MIC ratio (or the AUC/MIC ratio). This is the case for aminoglycosides and fluoroquinolones, and for both classes a peak/MIC ratio of at least 10 within the first 24 h of treatment has been shown to result in around 90% bacteriological as well as clinical cure. One consequence of clinical dosing has been the once-a-day (OD) dosing for aminoglycosides, which is the standard mode of therapy in many countries. Clinical studies in the field of antibacterial PD are still relatively scarce, and much information is needed to enable relevant dosing strategies for all types of antibiotics against all common infections and micro-organisms.
Frimodt-Møller
Niels
N
Microbiological R&D, Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark. nfm@ssi.dk
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards*; D013045:Species Specificity; D013997:Time Factors
D000900:Anti-Bacterial Agents